Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 85

Sort by

Sort Order Select

Journal Articles

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Omar Alzarkali, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2025-3393

Published: 2025

Journal Articles

Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes

Julie Braish, Najla Al Ali, Zena Komrokji, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 240.

https://doi.org/10.1182/blood-2025-240

Published: 2025

Journal Articles

Balancing the treatment outcomes: Survival and quality of life among older adults with AML

Sara Tinsley-Vance, Cecile Lengacher, David Sallman, Rami Komrokji, Steven Sutton, Onyee Chan, Kendra Sweet, Andrew Kuykendall, Areej El-Jawahri, Martine Extermann, Eric Padron, Ram Thapa, Daniel Lastorino, Jeffrey Lancet

Blood (2025) 146 (Supplement 1): 6405.

https://doi.org/10.1182/blood-2025-6405

Published: 2025

Journal Articles

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Kendra Sweet, Alison Walker, Jeffrey Lancet, Eric Padron, David Sallman, Rami Komrokji

Blood (2025) 146 (Supplement 1): 3856.

https://doi.org/10.1182/blood-2025-3856

Published: 2025

Journal Articles

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

Abigail Huetteman, Najla Al Ali, David Sallman, Eric Padron, Andrew Kuykendall, Onyee Chan, Zhuoer Xie, Alison Walker, Seongseok Yun, Samuel Reynolds, Kendra Sweet, Rami Komrokji, Jeffrey Lancet

Blood (2025) 146 (Supplement 1): 3853.

https://doi.org/10.1182/blood-2025-3853

Published: 2025

Journal Articles

IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies

Rami Komrokji, Amin Azem, Zena Komrokji, Najla Al Ali, Zhuoer Xie, Onyee Chan, Samuel Reynolds, Seongseok Yun, Alison Walker, Kendra Sweet, Andrew Kuykendall, Jeffrey Lancet, Eric Padron, David Sallman

Blood (2025) 146 (Supplement 1): 3851.

https://doi.org/10.1182/blood-2025-3851

Published: 2025

Journal Articles

Interim Results of the CMML scrna-seq atlas: GMP skewing is independently associated with overall survival in CMML.

Blood (2025) 146 (Supplement 1): 3840.

https://doi.org/10.1182/blood-2025-3840

Published: 2025

Journal Articles

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

Andrew Kuykendall, Francesca Palandri, Bella Vo, Fulya Sen Nikitas, Nicholas Meader, Shiyuan Zhang, Tom (sizhu) Liu, Shuang Wang, Gautam Sajeev, Mirko Fillbrunn, James Signorovitch, Jasmine Sahni, Dwaipayan Patnaik, Aaron Gerds

Blood (2025) 146 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2025-2031

Published: 2025

Journal Articles

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

Rami Komrokji, Najla Al Ali, Zena Komrokji, Zhuoer Xie, Onyee Chan, Andrew Kuykendall, Seongseok Yun, Rory Shallis, Samuel Reynolds, Alison Walker, Kendra Sweet, Jeffrey Lancet, Eric Padron, David Sallman

Blood (2025) 146 (Supplement 1): 2072.

https://doi.org/10.1182/blood-2025-2072

Published: 2025

Journal Articles

Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis

John Mascarenhas, Andrew Kuykendall, Terrence Bradley, Bart Scott, Habte Yimer, Yiqun Yang, Fei Huang, Ying Wan, Shyamala Navada, Judy Ho, Tymara Berry, Salman Otoukesh

Blood (2025) 146 (Supplement 1): 2052.

https://doi.org/10.1182/blood-2025-2052

Published: 2025

Journal Articles

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

Noushin Farnoud, Kamal Menghrajani, Paola Guglielmelli, Christopher Famulare, Erin McGovern, Giuseppe Gaetano Loscocco, Andriy Derkach, Andrew Dunbar, Naseema Gangat, Vikas Gupta, Andrea Arruda, Taghi Manshouri, Srdan Verstovsek, Andrew Kuykendall, Vincent Ho, Auro Viswabandya, Joachim Deeg, Thomas Monahan, Tania Jain, Jeanne Palmer, Alla Keyzner, Aaron Gerds, Alexandra Gomez-Arteaga, Nikolai Podoltsev, Roni Tamari, Helen Ajufo, Satyajit Kosuri, Haris Ali, Idoroenyi Amanam, Jordan Chervin, Minal Patel, Jesús Gutiérrez-Abril, Sarun Sereewattanawoot, Juan Arango Ossa, Francesco Passamonti, Francesco Maura, Maymona Abdelmagid, Ahmed Abdelrheem, Yassin Bashir, Muhammad Yousuf, Animesh Pardanani, Kapila Viges, David Shoultz, Rick Winneker, Omar Abdel-Wahab, John Mascarenhas, Ronald Hoffman, Ross Levine, Elli Papaemmanuil, Alessandro Vannucchi, Ayalew Tefferi, Raajit Rampal

Blood (2025) 146 (Supplement 1): 2046.

https://doi.org/10.1182/blood-2025-2046

Published: 2025

Journal Articles

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Andrew Kuykendall, Rupali Roy, Abdulraheem Yacoub, Marina Kremyanskaya, Aaron Gerds, Ronald Paquette, Jeanne Palmer, Kathryn Johnson, Heidi Kosiorek, Amylou Dueck, Carolyn Mead-Harvey, Ashley Yu, Rami Komrokji, Raajit Rampal, Ruben Mesa, Ronald Hoffman, John Mascarenhas

Blood (2025) 146 (Supplement 1): 483.

https://doi.org/10.1182/blood-2025-483

Published: 2025

Journal Articles

Investigating the clonal and biological underpinnings of systemic mastocytosis with an associated hematological neoplasm

Nana Adjoa Ben-Crentsil, Somedeb Ball, Hannah Newman, Christopher Ryder, Surendra Neupane, Anthony Hunter, Yu-Hung Wang, Kiran Batta, Kristian Gurashi, Traci Kruer, Maria Balasis, Ariel Quintana, Rami Komrokji, David Sallman, Andrew Kuykendall, Tracy George, Daniel Wiseman, Eric Padron

Blood (2025) 146 (Supplement 1): 3763.

https://doi.org/10.1182/blood-2025-3763

Published: 2025

Journal Articles

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Blood (2025) 146 (Supplement 1): 81.

https://doi.org/10.1182/blood-2025-81

Published: 2025

Journal Articles

Racial disparities in genomic alterations and survival outcomes in Acute Myeloid Leukemia (AML)

Utsav Joshi, Fatima Tuz Zahra, Pujan Patel, Najla Al Ali, Zachary Thompson, Nagehan Pakasticali, Jinming Song, Rory Shallis, Zhuoer Xie, Seongseok Yun, Andrew Kuykendall, Eric Padron, Alison Walker, David Sallman, Rami Komrokji, Jeffrey Lancet, Mohammad Hussaini, Onyee Chan

Blood (2025) 146 (Supplement 1): 4630.

https://doi.org/10.1182/blood-2025-4630

Published: 2025

Journal Articles

Early real-world experience with revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability

Umar Iqbal, Onyee Chan, Rory Shallis, Lorena Lopez-Gonzalez, Syeda Saba Kareem, Alison Walker, Craig Freyer, Andrew Kuykendall, Huan Huang, Zhuoer Xie, Eric Padron, Rami Komrokji, Jeffrey Lancet, David Sallman

Blood (2025) 146 (Supplement 1): 3448.

https://doi.org/10.1182/blood-2025-3448

Published: 2025

Journal Articles

Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)

Fatima Tuz Zahra, Ekrem Turk, Najla Al Ali, Sean Haney, Dimitrios Drekolias, Nicole Vincelette, Jinming Song, Samuel Reynolds, Rory Shallis, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Eric Padron, Alison Walker, David Sallman, Rami Komrokji, Jeffrey Lancet, Seongseok Yun, Onyee Chan

Blood (2025) 146 (Supplement 1): 291.

https://doi.org/10.1182/blood-2025-291

Published: 2025

Journal Articles

Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy

Blood (2025) 146 (Supplement 1): 4291.

https://doi.org/10.1182/blood-2025-4291

Published: 2025

Journal Articles

Clinical features and outcomes of myelofibrosis patients with MPL mutations

Yu-Han Chen, Shruti Gajjar, Victor You, Rami Komrokji, Valentina Nardi, Harrison Tsai, Andrew Kuykendall, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 5601.

https://doi.org/10.1182/blood-2025-5601

Published: 2025

Journal Articles

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Andrew Kuykendall, Douglas Tremblay, Anthony Hunter, Pankit Vachhani, Alexander Coltoff, Anand Patel, Ashwin Kishtagari, Jeremy DiGennaro, Dahniel Sastow, Sandra Jones, Jay Jarodiya, Georgio Medawar, Shiv Shah, Naimisha Marneni, Megan Metzger, Ashley Yu, Rami Komrokji, John Mascarenhas

Blood (2025) 146 (Supplement 1): 5600.

https://doi.org/10.1182/blood-2025-5600

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Setting the stage in KMT2A rearranged acute myelogenous leukemia in the era of menin inhibitors

Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes

Balancing the treatment outcomes: Survival and quality of life among older adults with AML

Elevated serum erythropoietin level is associated with unique clinical and genomic features, response to treatment, and outcomes in lower-risk myelodysplastic syndromes

Outcomes of hypomethylating agent (HMA)-based therapy in patients with myelodysplastic syndrome with fibrosis

IDH mutant MDS: Proposal for disease subset recognition based on molecular and clinical features, and the availability of targeted therapies

Interim Results of the CMML scrna-seq atlas: GMP skewing is independently associated with overall survival in CMML.

Survival and clinical outcomes in patients with myelofibrosis and new or worsening anemia treated with ruxolitinib: A systematic review and meta-analysis

The role of hypomethylating agents and venetoclax combination in higher risk myelodysplastic syndromes

Improvemf: Phase 1b trial of imetelstat plus ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis

Clonal persistence and early cooperative mutations shape transformation in myelofibrosis

A phase 2 study of canakinumab in patient with myelofibrosis: Results from part 1

Investigating the clonal and biological underpinnings of systemic mastocytosis with an associated hematological neoplasm

Rusfertide or placebo plus current standard-of-care therapy for polycythemia vera: Durability of response and safety results through week 52 from the randomized controlled phase 3 VERIFY study

Racial disparities in genomic alterations and survival outcomes in Acute Myeloid Leukemia (AML)

Early real-world experience with revumenib outside of a clinical trial setting: A single center retrospective review of efficacy and tolerability

Outcomes and characteristics of patients treated with frontline intensive chemotherapy versus hypomethylating agent/venetoclax-based therapy in DDX41-mutated Acute Myeloid Leukemia (AML)

Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy

Clinical features and outcomes of myelofibrosis patients with MPL mutations

An independent, multi-center analysis of the post-approval utilization and efficacy of pacritinib and momelotinib in patients with myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only